{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:09:59Z","timestamp":1790298599775,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2008,8,29]],"date-time":"2008-08-29T00:00:00Z","timestamp":1219968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>Metastatic small bowel adenocarcinoma (SBA) has a poor prognosis. Because of the rarity of SBA, only a few studies have evaluated the role of chemotherapy in the treatment of metastatic SBA; thus, the benefit, if any, of adding a platinum compound to fluorouracil (5\u2010FU) is unknown. The objective of this retrospective study was to determine whether the addition of a platinum compound to 5\u2010FU provided any benefit in the treatment of patients with metastatic SBA.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>The authors identified 80 patients with metastatic SBA who were treated with chemotherapy at the University of Texas M. D. Anderson Cancer Center between 1978 and 2005. Response rates, progression\u2010free survival (PFS), and overall survival (OS) were compared between patients who received 5\u2010FU and a platinum compound and patients who received other chemotherapy combinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>The median patient age was 53 years. The primary tumor site was the jejunum in 35 patients (43%), duodenum in 30 patients (38%), ileum in 6 patients (8%), and nonspecified small bowel in 9 patients (11%). Of all 80 patients, 29 patients (36%) received 5\u2010FU and a platinum compound, 41 patients (51%) received 5\u2010FU without a platinum compound, and 10 patients (13%) received non\u20105\u2010FU\u2013based treatment. Compared with other chemotherapy regimens, treatment with 5\u2010FU and a platinum agent resulted in a higher response rate (46% vs 16% with other regimens; <jats:italic>P<\/jats:italic> = .01) and longer median PFS (8.7 months vs 3.9 months; <jats:italic>P<\/jats:italic> \u2264 .01) but not better OS (14.8 months vs 12 months; <jats:italic>P<\/jats:italic> = .1). In multivariate analysis, treatment with 5\u2010FU and a platinum compound was a significant predictor of response (odds ratio, 4.5; 95% confidence interval [CI], 1.3\u201015.8; <jats:italic>P<\/jats:italic> = .02) and PFS (hazard ratio. 0.49; 95% CI, 0.29\u20100.84; <jats:italic>P<\/jats:italic> = .01) but only reached borderline significance for OS (hazard ratio, 0.63; 95% CI, 0.37\u20101.07; <jats:italic>P<\/jats:italic> = .08).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>To the authors' knowledge, the current analysis represents the largest number of patients with metastatic SBA treated with chemotherapy in the literature, and the results suggested that the combination of 5\u2010FU and a platinum compound leads to a higher response rate and PFS compared with other chemotherapy regimes. The authors concluded that prospective investigation of platinum analogues in the treatment of SBA is warranted. Cancer 2008. \u00a9 2008 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.23822","type":"journal-article","created":{"date-parts":[[2008,8,29]],"date-time":"2008-08-29T10:57:12Z","timestamp":1220007432000},"page":"2038-2045","source":"Crossref","is-referenced-by-count":105,"title":["Chemotherapy with 5\u2010fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma"],"prefix":"10.1002","volume":"113","author":[{"given":"Michael J.","family":"Overman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo M.","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fogelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Abbruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaffer A.","family":"Ajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,10,3]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/25.4.722"},{"key":"e_1_2_5_3_2","first-page":"653","article-title":"Incidence of histologic types of cancer of the small intestine","volume":"78","author":"Weiss NS","year":"1987","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.56.2.106"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2693::AID-CNCR14>3.0.CO;2-U"},{"key":"e_1_2_5_6_2","unstructured":"CzaykowskiP.Chemotherapy for small bowel adenocarcinoma (SBA): experience over a 10\u2010year period at the BC Cancer Agency[abstract]. Presented at the American Society of Clinical Oncology 2004 Gastrointestinal Cancers Symposium San Francisco California January 22\u201024 2004. Abstract 109."},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20404"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01. coc.0000214931.01062.01"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(65)80101-5"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-2-132"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840101)53:1<23::AID-CNCR2820530106>3.0.CO;2-U"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.2938"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.261"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.523"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1159\/000089678"},{"key":"e_1_2_5_16_2","unstructured":"OvermanMJ ChedidS MorrisJ et al.A phase II study of capecitabine and oxaliplatin (CAPOX) in metastatic adenocarcinoma of the small bowel or ampulla of Vater[abstract]. Presented at the American Society of Clinical Oncology 2007 Gastrointestinal Cancers Symposium Orlando Florida January 19\u201021 2007. Abstract 139."},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10350-004-6457-9"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970304)70:5<512::AID-IJC4>3.0.CO;2-0"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02303522"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02303567"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O"},{"key":"e_1_2_5_23_2","first-page":"26S","article-title":"Final response data of a phase II study of capecitabine and oxaliplatin (CAPOX) in advanced adenocarcinoma of the small bowel or ampulla of Vater","author":"Overman MJ","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_24_2","unstructured":"EnzingerPC EarleC ZhuA et al.Phase I dose\u2010finding and pharmacologic study of cisplatin irinotecan and either capecitabine or infusional 5\u2010FU in patients with advanced gastrointestinal malignancies[abstract]. Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium Hollywood Florida January 27\u201029 2005. Abstract 28."},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.238"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9610(77)90399-3"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23822","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:57:35Z","timestamp":1760284655000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,3]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2008,10,15]]}},"alternative-id":["10.1002\/cncr.23822"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23822","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,3]]}}}